Scott L. Friedman
Corporate Officer/Principal bij Icahn School of Medicine at Mount Sinai
Oorsprong van het eerstegraads netwerk van Scott L. Friedman
| Entiteit | Type entiteit | Industrie | |
|---|---|---|---|
Icahn School of Medicine at Mount Sinai
47
| College/University | Other Consumer Services | 47 |
Forbion Capital Partners Management Holding BV
 Forbion Capital Partners Management Holding BV Investment ManagersFinance Forbion Capital Partners Management Holding BV (Forbion) is a Netherlands-based venture capital firm which was founded by Bart Bergstein. Headquartered in Naarden, the firm specializes in late-stage and early-stage clinical development programs to optimize the commercial potential of their investee company's technologies.
35
| Private Company | Investment Managers | 35 |
Grafiek van bedrijven verbonden in de tweede graad
Connectie in verschillende bedrijven
Bedrijven verbonden met Scott L. Friedman via zijn persoonlijke netwerk
| Onderneming | Sector | Gelieerde personen | Hoofdpost |
|---|---|---|---|
| The Trustees of Columbia University in The City of New York | College/University | Graduate Degree Corporate Officer/Principal Doctorate Degree Undergraduate Degree Masters Business Admin Corporate Officer/Principal Corporate Officer/Principal Doctorate Degree | |
The Mount Sinai Hospital
 The Mount Sinai Hospital Hospital/Nursing ManagementHealth Services The Mount Sinai Hospital provides medical and healthcare services. The company was founded in 1952 and is headquartered in New York, NY. | Hospital/Nursing Management | Director/Board Member Corporate Officer/Principal Corporate Officer/Principal Corporate Officer/Principal Corporate Officer/Principal Director/Board Member Chief Investment Officer Chief Tech/Sci/R&D Officer | |
NewAmsterdam Pharma BV
 NewAmsterdam Pharma BV Pharmaceuticals: MajorHealth Technology NewAmsterdam Pharma BV develops novel drugs to treat dyslipidemia. It operates as a biotechnology company and develops anti-dyslipidemic compounds in cardiovascular disease indications. The firm's product DEZ-001 develops a potent cholesteryl ester transfer protein inhibitor that has shown a decrease of low-density lipoprotein levels, and an increase of high-density lipoprotein levels. The company was founded by John J. P. Kastelein in 2012 and is headquartered in Naarden, the Netherlands. | Pharmaceuticals: Major | Founder Chairman Chief Tech/Sci/R&D Officer Director/Board Member Chief Operating Officer Director/Board Member | |
| University of Groningen | College/University | Graduate Degree Graduate Degree Graduate Degree Doctorate Degree Doctorate Degree Graduate Degree | |
VectorY BV
 VectorY BV Miscellaneous Commercial ServicesCommercial Services VectorY BV is a biotech company based in Amsterdam, Netherlands, that is dedicated to developing transformative medicines for people with neurodegenerative diseases such as ALS, Huntington's, and Parkinson's. VectorY's platform combines the promise of precise therapeutic antibodies with one-time AAV-based delivery to the CNS, enabling long-lasting CNS treatment after a single administration using cutting-edge antibody, AAV, and manufacturing technologies. The Dutch company's unique in-house expertise in antibodies, AAV vectors, protein degradation, manufacturing, and neuroscience drives the rapid development of much-needed disease-modifying therapies for neurodegenerative diseases. The company was founded by Sander J. van Deventer and Pavlina Konstantinova, with Sander J. van Deventer serving as the CEO since incorporation. | Miscellaneous Commercial Services | Chief Executive Officer Director/Board Member Director/Board Member Chairman Corporate Officer/Principal | |
| University of Amsterdam | College/University | Doctorate Degree Undergraduate Degree Doctorate Degree Corporate Officer/Principal | |
Oxitope Pharma BV
 Oxitope Pharma BV Pharmaceuticals: MajorHealth Technology Oxitope Pharma BV is a Dutch pharmaceutical start-up founded in 2020 that focuses on discovering and developing medicine for the treatment of inflammatory and cardiovascular diseases caused by oxidative stress. The company is based in Naarden, Netherlands. The Dutch company takes a different approach to the diagnosis and treatment of these diseases by preventing, halting, or reversing acute and chronic diseases driven by oxidized phospholipids. Oxitope Pharma's goal is to enable people to live long and healthy lives. The CEO is John Montana. | Pharmaceuticals: Major | Chief Executive Officer Director/Board Member Director/Board Member Director/Board Member | |
| UNIQURE N.V. | Biotechnology | Chairman Founder Director/Board Member | |
Exosome Diagnostics, Inc.
 Exosome Diagnostics, Inc. Medical/Nursing ServicesHealth Services Exosome Diagnostics, Inc. develops and commercializes biofluid-based diagnostics to deliver personalized precision healthcare that improves lives. Its novel exosome-based technology platform can yield comprehensive and dynamic molecular insights to transform how cancer and other serious diseases are detected, diagnosed, treated and monitored. The company was founded by Wayne D. Comper, Harvey J. Barnett and James R. McCullough and is headquartered in Waltham, MA. | Medical/Nursing Services | Chief Tech/Sci/R&D Officer Director/Board Member Director/Board Member | |
Complement Therapeutics Ltd.
 Complement Therapeutics Ltd. Pharmaceuticals: MajorHealth Technology Complement Therapeutics Ltd. develops medicines that target the complement system. The British company was founded by Richard Unwin, Simon J. Clark, and Paul Bishop. The CEO is Rafiq Hasan. | Pharmaceuticals: Major | Director/Board Member Director/Board Member Director/Board Member | |
The Mount Sinai Health System, Inc.
 The Mount Sinai Health System, Inc. Medical/Nursing ServicesHealth Services The Mount Sinai Health System, Inc. provides health care system services. It is an integrated health care system providing exceptional medical care to our local and global communities. The company is headquartered in New York, NY. | Medical/Nursing Services | Director/Board Member Corporate Officer/Principal Corporate Officer/Principal | |
| New York University | College/University | Corporate Officer/Principal Undergraduate Degree Graduate Degree | |
| GENEDX HOLDINGS CORP. | Medical/Nursing Services | Director/Board Member Chief Executive Officer Corporate Officer/Principal | |
Academic Medical Center
 Academic Medical Center Hospital/Nursing ManagementHealth Services Academic Medical Center operates a medical center and a medical research facility. It also provides education and training. The company was founded in 1983 and is headquartered in Amsterdam, the Netherlands. | Hospital/Nursing Management | Corporate Officer/Principal Corporate Officer/Principal Corporate Officer/Principal | |
NorthSea Therapeutics BV
 NorthSea Therapeutics BV BiotechnologyHealth Technology NorthSea Therapeutics BV operates as a biotechnology company. It develops oral, structurally engineered fatty acid therapeutics. The company was founded by Hilde H. Steineger and David A. Fraser and is headquartered in Naarden, the Netherlands. | Biotechnology | Director/Board Member Director/Board Member Director/Board Member | |
Xention Pharma Ltd.
 Xention Pharma Ltd. Pharmaceuticals: MajorHealth Technology Xention Pharma Ltd. develops and researches drugs. The firm develops novel therapies for the treatment of atrial fibrillation; modulators of IKur and IKACh for atrial fibrillation. The company was founded by John W. Word and is headquartered in Newmarket, the United kingdom. | Pharmaceuticals: Major | Director/Board Member Chief Tech/Sci/R&D Officer Founder | |
Inversago Pharma, Inc.
 Inversago Pharma, Inc. Pharmaceuticals: MajorHealth Technology Inversago Pharma, Inc. develops novel gastrointestinal drugs. The company was founded by Fran?ois Ravenelle in and is headquartered in Montreal, Canada. | Pharmaceuticals: Major | Director/Board Member Chairman Director/Board Member | |
NewAmsterdam Pharma Holding BV
 NewAmsterdam Pharma Holding BV BiotechnologyHealth Technology Part of NewAmsterdam Pharma Co. NV, NewAmsterdam Pharma Holding BV is a Dutch company that engages in research and development of transformative therapies for cardio metabolic diseases. The company is based in Naarden, the Netherlands. The company was founded in 2019 by John Jacob Pieter Kastelein. Michael H. Davidson has been the CEO of the company since 2020. NewAmsterdam Pharma Holding was acquired by Frazier Lifesciences Acquisition Corp. on November 22, 2022 for $468.74 million. | Biotechnology | Chairman Director/Board Member Founder | |
Prexton Therapeutics SA
 Prexton Therapeutics SA Pharmaceuticals: MajorHealth Technology Prexton Therapeutics SA operates as a biopharmaceutical company which develops novel therapeutic compounds as a new treatment for Parkinson’s disease and other brain disorders. The company was founded by Francois Conquet in 2012 and is headquartered in Geneva, Switzerland. | Pharmaceuticals: Major | Director/Board Member Founder Director/Board Member | |
| University of Utrecht | College/University | Corporate Officer/Principal Doctorate Degree Graduate Degree | |
| Oxyrane, Ltd. | Chairman Director/Board Member | ||
BioVex, Inc.
 BioVex, Inc. Pharmaceuticals: MajorHealth Technology BioVex, Inc. develops vaccines for the treatment of cancer and the prevention of chronic infectious diseases. Its products include OncoVEX oncolytic and ImmunoVEX technology. The company was founded in 1999 by Dr. Robert Coffin and is headquartered in Woburn, MA. | Pharmaceuticals: Major | Chief Executive Officer Director/Board Member | |
| REPLIMUNE GROUP, INC. | Biotechnology | Founder Director/Board Member | |
Azafaros BV
 Azafaros BV Pharmaceuticals: MajorHealth Technology Azafaros BV develops therapeutic agents for the treatment of rare metabolic disorders. The company was founded on July 1, 2018 and is headquartered in Leiden, the Netherlands. | Pharmaceuticals: Major | Director/Board Member Chairman | |
BioVex Group, Inc.
 BioVex Group, Inc. BiotechnologyHealth Technology BioVex Group, Inc. operates as a clinical-stage biotechnology company. It focuses on the development and commercialization of targeted treatments for cancer and the prevention of infectious disease. The company was founded in 1999 and is headquartered in Woburn, MA. | Biotechnology | Chief Executive Officer Director/Board Member | |
Cancer Research UK
 Cancer Research UK Miscellaneous Commercial ServicesCommercial Services Cancer Research UK provides cancer research services. It supports and undertakes research on the biology and causes of cancer and develops anti-cancer drugs. The firm also provides general information about cancer and types of treatments and funds projects that help patients cope with the side effects of cancer and its treatment. Its institute also operates an online portal CancerHelp UK that provides patient information. The company was founded in 2001 and is headquartered in London, the United Kingdom. | Miscellaneous Commercial Services | Corporate Officer/Principal Director/Board Member | |
| Princeton University | College/University | Undergraduate Degree Doctorate Degree | |
| University of Medicine & Dentistry of New Jersey | College/University | Doctorate Degree Doctorate Degree | |
| Harvard Medical School | College/University | Corporate Officer/Principal Doctorate Degree | |
Novo Ventures 1 A/S
 Novo Ventures 1 A/S Investment ManagersFinance Novo Ventures (Novo Ventures) is a venture capital operating division of Novo Nordisk Fonden. It engages in investment activities. The firm was established in 1999, and is headquartered in Hellerup, Denmark. | Investment Managers | Corporate Officer/Principal Private Equity Analyst | |
| Rutgers State University of New Jersey | College/University | Doctorate Degree Undergraduate Degree | |
| University of California San Diego | College/University | Corporate Officer/Principal Doctorate Degree | |
Mestag Therapeutics Ltd.
 Mestag Therapeutics Ltd. Financial ConglomeratesFinance Mestag Therapeutics Ltd. is engaged in the biotechnology industry. The company was founded on February 17, 2020 and is headquartered in Cambridge, the United Kingdom. | Financial Conglomerates | Chairman Director/Board Member | |
Synox Therapeutics Ltd.
 Synox Therapeutics Ltd. BiotechnologyHealth Technology Synox Therapeutics Ltd. a clinical stage biopharmaceutical company. The company is headquartered in Dublin, Ireland. | Biotechnology | Chairman Director/Board Member | |
| ENGENE HOLDINGS INC. | Biotechnology | Director/Board Member Director/Board Member | |
Inthera Bioscience AG
 Inthera Bioscience AG BiotechnologyHealth Technology Inthera Bioscience AG engages in the research in as well as development, production, and distribution of pharmaceutical, biological, and other products used in the fields of human and veterinary medicine. It also provides related consultancy services. The company was founded by Ulrich Kessler and Paramjit Singh Arora on September 20, 2013 and is headquartered in Zurich, Switzerland. | Biotechnology | Chairman Director/Board Member | |
Metrion Biosciences Ltd.
 Metrion Biosciences Ltd. BiotechnologyHealth Technology Metrion Biosciences Ltd. is a contract research organization that specializes in providing drug discovery services to pharmaceutical and bioscience customers. Metrion Biosciences is based in Great Abington, UK and was founded in 2015. The British company offers a range of high-quality ion channel assays on a fee-for-service or collaboration basis, including an industry-leading panel of in vitro cardiac ion channel safety assays, translational native cell and phenotypic assays for neurological and cardiotoxicity testing, and a range of other ion channel screening services such as cell line development and optimization. Andrew Southan has been the CEO of the company since 2016. | Biotechnology | Director/Board Member Director/Board Member | |
| University of Leiden | College/University | Doctorate Degree Corporate Officer/Principal | |
| University of Cambridge | College/University | Corporate Officer/Principal Masters Business Admin | |
| NOVO NORDISK A/S | Pharmaceuticals: Major | Corporate Officer/Principal Corporate Officer/Principal | |
| Vrije Universiteit Amsterdam | College/University | Undergraduate Degree Graduate Degree | |
Xention Ltd.
 Xention Ltd. Pharmaceuticals: MajorHealth Technology Part of Xention Pharma Ltd., Xention Ltd. is a British company that develops and researches drugs. The company is based in Newmarket, UK. Xention was founded in 2002. | Pharmaceuticals: Major | Director/Board Member Director/Board Member | |
| DYNE THERAPEUTICS, INC. | Biotechnology | Director/Board Member Director/Board Member | |
Mount Sinai Genomics, Inc.
 Mount Sinai Genomics, Inc. Medical/Nursing ServicesHealth Services Mount Sinai Genomics, Inc. operates online predictive health analysis platform for diagnosis, treatment and prevention of diseases. It offers Centrellis which analyzes and interprets extensive information about known inherited diseases, including related mutations, frequency across populations, and the penetrance and expressivity of genetic changes. The company was founded by Eric Schadt and is headquartered in Stamford, CT. | Medical/Nursing Services | Director/Board Member Founder | |
| Yale University | College/University | Corporate Officer/Principal Undergraduate Degree |
Statistieken
Internationaal
| Verenigde Staten | 19 |
| Nederland | 13 |
| Verenigd Koninkrijk | 11 |
| Canada | 3 |
| Zwitserland | 3 |
Sectoraal
| Health Technology | 23 |
| Consumer Services | 15 |
| Health Services | 7 |
| Finance | 5 |
| Commercial Services | 3 |
Operationeel
| Director/Board Member | 327 |
| Corporate Officer/Principal | 186 |
| Founder | 64 |
| Chief Tech/Sci/R&D Officer | 60 |
| Chairman | 57 |
Sterkste connecties
| Insiders | |
|---|---|
| Steve Hochberg | 47 |
| Hugo Slootweg | 34 |
| Patrick Volkert Vink | 30 |
| Nanna Liebach Lüneborg | 29 |
| Michael Hayden | 27 |
| Andrew Russell | 26 |
| Tom Strauss | 26 |
| Peter Andersen | 26 |
| Geert-Jan Mulder | 17 |
| Jeffrey Vacirca | 17 |
| Sander J. van Deventer | 17 |
| Michael Donovan | 16 |
| Marco Boorsma | 15 |
| Jasper Bos | 15 |
| Carlo Incerti | 14 |
- Beurs
- Insiders
- Scott L. Friedman
- Bedrijfsconnecties
